News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

October 5, 2010

Kyowa Hakko Kirin to enter licensing agreement with
Lundbeck for A2a antagonist KW-6356

Tokyo, October 5, 2010 -Today, Kyowa Hakko Kirin Co., Ltd. ((Kyowa Hakko Kirin) Tokyo Japan; President, Yuzuru Matsuda) has formed a licensing agreement with H. Lundbeck A/S, ((Lundbeck) CEO, Ulf Wiinberg) for the development and commercialization Kyowa Hakko Kirin adenosine A2a antagonist KW-6356.

Lundbeck has been given the exclusive rights for KW-6356 globally, except for Japan and the Asian region. Lundbeck will also have the right to select other A2a antagonists from Kyowa Hakko's inhibitor group with the aim of developing back-up compounds and indications. Under the licensing agreement to develop and commercialize KW-6356, Kyowa Hakko Kirin will receive from Lundbeck an upfront payment, development and commercial milestones, as well as royalties on net sales.

KW-6356 has a high affinity to the adenosine A2a receptors, has a new mechanism that selectively counteracts the activation of the receptors. It is a potential treatment for a wide range of diseases including Parkinson's disease. Kyowa Hakko Kirin KW-6356 is currently in pre-clinical trials and following on from Permax, KW-6500, KW-6002, is expected to contribute to new therapies of Parkinson's disease.

About Lundbeck
1. Company: Lundbeck, a global pharmaceutical company has conducted research, development, manufacture and sales of therapeutic drugs for central nervous system disorders for over 50 years.
2. Established: 1915
3. Annual sales: About ¥233.5 billion (1 Danish krone = ¥17)
4. Number of staff:      5,900
5. CEO: Ulf Wiingberg
6. Location: Copenhagen, Denmark

To Page Top